Table III.
Apoptosis rates of U251 cells in distinct groups.
| Group | Concentration, µmol/l | Early stage, % | Late stage, % | Total apoptosis, % |
|---|---|---|---|---|
| Control | (1.6±0.54) | (0.8±0.03) | (2.4±1.03) | |
| TMZ | 200 | (22.8±2.24)a | (3.1±0.75)a | (25.9±3.15)a |
| PDTC | 20 | (2.0±1.41)a | (2.7±0.43)a | (17.9±1.26)a |
| 50 | (25.8±0.85)b | (5.8±0.91)b | (31.6±1.75)b | |
| 80 | (59.8±2.09)c | (4.1±1.46) | (63.9±4.24)c | |
| 100 | (71.7±2.76)d | (22.5±2.07)d | (93.2±4.73)d | |
| TMZ + PDTC | 20 | (26.6±2.27)e | (6.7±0.85)e | (33.3±2.44)e |
| 50 | (70.2±5.12)f | (21.5±2.57)f | (91.7±5.22)f | |
| 80 | (64.1±3.04) | (33.2±2.06)g | (97.3±4.46)g | |
| 100 | (57.7±3.55) | (39.2±2.89)h | (96.9±5.10) |
Data were presented as the mean ± standard deviation.
P<0.05, vs. control group
P<0.05, vs. control group and 20 µmol/l PDTC group
P<0.05, vs. control group and 50 µmol/l PDTC group
P<0.05, vs. control group and 80 µmol/l PDTC group
P<0.05, vs. TMZ group and 20 µmol/l PDTC group
P<0.05, vs. TMZ group, 50 μmol/l PDTC group and TMZ + 20 µmol/l PDTC group
P<0.05, vs. TMZ group, 80 µmol/l PDTC group and TMZ + 50 µmol/l PDTC group
P<0.05, vs. TMZ group, 100 µmol/l PDTC group and TMZ + 80 µmol/l PDTC group. All comparisons were carried out using one-way analysis of variance followed by least significant difference analysis or by the Kruskal-Wallis test. TMZ, temozolomide; PDTC, pyrrolidine dithiocarbamate.